Led - I disagree with your comment that beefing up the BoM trail with more patients will be negative. From my understanding if the DSMB says add more patients to the trial it means that we have at least 25% RRR but not 30%. If I recall one of Bears previous posts he said that one of the most prescribed drugs today has around 14% RRR. 25% RRR with a good safety profile is a pretty awesome number that in theory would be welcomed by the payers. To me, and I suspect many that would be good news. Adding 10 - 12 months to the trial may spook a few but someone like me will be more than happy to assume their position at that time. 25% RRR is a great number.

tada